Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Immunotherapy and Fibrosis Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for RGMB drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | RGMB ECD-Fc / Mutant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed (Native Glycosylation). |
View RGMB Products |
| Gene Delivery | RGMB Promise-ORF / Lentivirus Full-length ORF for stable cell lines. Sequence Verified. |
View RGMB Products |
| Benchmark Ab | Anti-RGMB Recombinant Positive Control High-affinity binding benchmark antibody. |
View RGMB Products |
| Validator | RGMB siRNA Set For knockdown verification in functional assays. |
View RGMB Products |
| Related Target A | PD-L2 Key functional partner; RGMB interacts with PD-L2 to regulate T-cell tolerance. |
View PD-L2 Products |
| Related Target B | BMP4 RGMB acts as a co-receptor for Bone Morphogenetic Proteins (BMPs) to modulate signaling pathways. |
View BMP4 Products |
| Related Target C | Neogenin High-affinity receptor interacting with RGMB to regulate cell migration and survival. |
View NEO1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Cross-species cyno/mouse evaluation | Human, Mouse, and Cynomolgus ortholog proteins available with >95% purity and validated mass spec profiles. |
| Subfamily counter screening (RGMA/RGMC) | Homolog panel proteins strictly verified by theoretical MW and sequence alignment to ensure zero cross-reactivity. |
| Lack of Controls | Recombinant Clinical Benchmark Antibodies included for reference binding assays. |
| False Positives | Sequence-verified siRNA included for target-specific knockdown validation. |
Live RGMB R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for RGMB therapeutics is intensifying, with major players shifting focus from traditional mAbs to multi-specific immune checkpoint modulators and anti-fibrotic agents. As first-generation therapies targeting the RGM family reach the clinic, the next wave of R&D is targeting the specific blockade of the RGMB-PD-L2 interface to overcome resistance in cold tumors.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibody | Emerging Biotechs, Academic Institutes | Solid Tumors, Inflammatory Airway Diseases | Blocking Assay (Need high-purity, native glycosylated ECD-Fc) |
| Bispecific Antibody | Immuno-oncology Innovators | Refractory Non-Small Cell Lung Cancer (NSCLC) | Dual-binding Validation (Need highly stable RGMB and PD-L2 co-proteins) |
| Soluble Decoy Receptor | Neurology & Fibrosis Specialists | Multiple Sclerosis, Hepatic Fibrosis | Selectivity Assay (Need Mutant vs WT Proteins to avoid RGMA/RGMC binding) |